Medicamen Biotech Ltd

₹ 270 4.18%

04 Sep - close price

medicamen.com BSE: 531146 NSE: MEDICAMEQ

About

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations^[1]

Key Points

Business Overview:^[1]^[2]^[3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.

Website BSE NSE

Market Cap ₹ 367 Cr.
Current Price ₹ 270
High / Low ₹ 454 / 210
Stock P/E 35.6
Book Value ₹ 206
Dividend Yield 0.37 %
ROCE 5.10 %
ROE 3.78 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter

Cons

The company has delivered a poor sales growth of 10.2% over past five years.
Company has a low return on equity of 4.85% over last 3 years.
Dividend payout has been low at 12.5% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	40.50	42.67	44.20	45.01	41.48	42.84	41.14	26.00	38.45	42.23	43.49	54.68	43.85
	33.09	36.51	38.61	38.18	36.62	36.29	34.90	27.10	34.42	37.18	38.41	50.56	39.07
Operating Profit	7.41	6.16	5.59	6.83	4.86	6.55	6.24	-1.10	4.03	5.05	5.08	4.12	4.78
OPM %	18.30%	14.44%	12.65%	15.17%	11.72%	15.29%	15.17%	-4.23%	10.48%	11.96%	11.68%	7.53%	10.90%
	0.38	0.55	0.83	0.54	0.58	0.29	0.14	5.22	0.47	0.37	0.53	1.73	0.86
Interest	0.96	0.91	0.65	1.87	0.68	1.01	0.73	0.62	0.56	0.84	0.78	0.60	0.64
Depreciation	1.68	1.80	1.76	1.77	1.74	2.57	2.17	0.47	1.77	1.81	1.75	1.73	1.74
Profit before tax	5.15	4.00	4.01	3.73	3.02	3.26	3.48	3.03	2.17	2.77	3.08	3.52	3.26
Tax %	14.37%	24.75%	31.17%	16.62%	25.17%	30.06%	27.59%	20.79%	24.42%	20.22%	15.58%	15.62%	22.39%
	4.42	3.01	2.77	3.10	2.26	2.27	2.52	2.41	1.64	2.21	2.59	2.97	2.53
EPS in Rs	3.49	2.38	2.19	2.44	1.78	1.79	1.98	1.90	1.21	1.63	1.91	2.19	1.87
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	78	67	82	112	123	117	110	115	138	172	151	179	184
	73	62	71	95	105	99	90	91	113	145	134	161	165
Operating Profit	5	6	12	17	17	18	20	24	25	27	17	18	19
OPM %	6%	8%	14%	15%	14%	15%	18%	21%	18%	16%	11%	10%	10%
	1	1	0	2	4	2	1	2	2	2	6	3	3
Interest	4	4	4	3	1	1	2	2	3	6	4	3	3
Depreciation	2	2	2	2	2	2	3	6	6	7	7	7	7
Profit before tax	0	1	6	14	18	17	17	18	17	17	13	12	13
Tax %	-267%	32%	19%	27%	31%	26%	25%	18%	13%	21%	26%	19%
	0	0	5	10	12	12	12	15	15	13	9	9	10
EPS in Rs	0.46	0.48	4.91	8.89	10.28	10.04	10.22	12.20	11.86	10.46	7.43	6.94	7.60
Dividend Payout %	0%	0%	0%	12%	10%	5%	10%	8%	8%	10%	13%	14%

Compounded Sales Growth
10 Years:	10%
5 Years:	10%
3 Years:	9%
TTM:	24%

Compounded Profit Growth
10 Years:	35%
5 Years:	-6%
3 Years:	-14%
TTM:	17%

Stock Price CAGR
10 Years:	4%
5 Years:	-16%
3 Years:	-27%
1 Year:	-23%

Return on Equity
10 Years:	8%
5 Years:	6%
3 Years:	5%
Last Year:	4%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	10	11	12	12	12	12	12	13	13	13	14
Reserves	8	8	16	63	75	110	122	136	181	196	205	266
	21	19	18	14	12	11	19	26	26	30	27	37
	31	23	29	28	38	43	39	52	57	55	48	45
Total Liabilities	69	60	73	118	137	176	192	226	277	294	293	362
	20	19	19	25	24	34	90	92	92	91	86	84
CWIP	0	0	0	0	15	40	0	0	0	0	0	0
Investments	0	0	0	0	0	2	2	2	4	8	8	8
	49	41	54	92	97	100	101	131	180	195	199	270
Total Assets	69	60	73	118	137	176	192	226	277	294	293	362

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-3	6	4	-5	4	12	13	5	-4	-0	-3	-29
	0	-1	-2	-8	-15	-39	-18	-8	-8	-9	-2	-3
	3	-5	-1	33	-4	21	6	4	28	3	-7	60
Net Cash Flow	-0	0	0	20	-14	-6	1	1	17	-6	-11	28
Free Cash Flow	-3	5	1	-14	-11	-26	-5	-4	-10	-6	-5	-34
CFO/OP	-65%	112%	31%	-29%	48%	88%	87%	33%	-27%	10%	-7%	-149%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	124	87	114	126	129	137	165	193	159	102	141	132
Inventory Days	95	95	102	77	67	85	28	188	230	237	274	258
Days Payable	187	160	165	118	134	160	161	291	232	152	182	138
Cash Conversion Cycle	32	22	51	85	62	62	32	91	157	188	234	252
Working Capital Days	7	3	34	89	116	139	130	146	151	117	186	197
ROCE %	12%	12%	24%	25%	20%	15%	13%	12%	11%	10%	7%	5%

Insights

In beta

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Permanent Employees
count

xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
xx			xx	xx	xx	xx	xx	xx
xx.xx					xx.xx	xx.xx	xx.xx	xx.xx
					xx	xx	xxx	xxx
					xx	xx		xx
				xxx			xxx	xxx
							xxx	xxx
			xx		xx

Please log in to see hidden values.

Number of Countries Served
count

Export Revenue Share
%

Domestic Marketing and Sales Team
count

Africa Share of Revenue
%

Products Registered Globally
count

Products Under Registration and Filing
count

R&D Team Size
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	43.21%	43.21%	43.21%	42.99%	42.99%	42.99%	43.16%	40.46%	40.46%	40.46%	40.46%	40.46%
	0.22%	0.22%	0.12%	0.06%	0.06%	0.06%	0.12%	0.00%	0.05%	0.02%	0.10%	0.07%
	0.20%	0.67%	0.99%	1.17%	1.17%	0.87%	0.69%	0.64%	0.59%	0.44%	0.00%	0.40%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.06%	0.05%	0.05%	0.05%	0.05%	0.05%
	56.38%	55.90%	55.69%	55.78%	55.79%	56.04%	55.99%	58.83%	58.84%	59.02%	59.39%	59.01%
No. of Shareholders	9,419	10,252	10,639	10,652	10,792	10,576	10,435	10,808	11,177	10,967	10,806	11,047

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	45.51%	45.37%	44.53%	44.77%	44.83%	43.60%	43.21%	43.21%	43.16%	40.46%	40.46%
	0.14%	0.49%	0.49%	0.47%	0.44%	0.40%	0.19%	0.12%	0.12%	0.10%	0.07%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%	0.99%	0.69%	0.00%	0.40%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.05%	0.05%
	54.35%	54.14%	54.99%	54.76%	54.73%	56.01%	56.40%	55.69%	55.99%	59.39%	59.01%
No. of Shareholders	4,095	4,802	4,684	4,542	4,965	9,300	8,233	10,639	10,435	10,806	11,047

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Nov 2024

Transcript

AI Summary
PPT
Dec 2021

Transcript

AI Summary
PPT
Nov 2020

Transcript

AI Summary
PPT
Aug 2020

Transcript

AI Summary
PPT
Jun 2020

Transcript

AI Summary
PPT